Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma
- 25 June 2025
- journal article
- case study
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 175 (1) , 453-461
Abstract
Purpose While checkpoint inhibitor therapy (CPI) has transformed treatment in multiple solid tumors, its efficacy in glioblastoma (GBM) remains limited. Understanding the molecular and clinical factors that influence glioblastoma’s response to CPI is essential to improving outcomes. Methods We identified patients with recurrent GBM, who had been treated with CPI and determined the association between their molecular, clinical, and demographic characteristics and survival outcomes. Results We identified 35 patients with recurrent GBM treated with CPI. PIK3CA mutation was associated with a statistically significant shorter OS duration, calculated from CPI initiation (p-value = 0.014). Tumor tissue without the mutation had less PD-1 expression in CD3+/CD8 + T cells. RB1 and TERT promoter mutations were associated with shorter PFS durations (p-value = 0.009, 0.053, respectively). Length of CPI therapy of more than 6 months was associated with increased PFS and OS (p-value = 0.069, 0.088, respectively), while steroid use at baseline was associated with a shorter OS (p-value = 0.0016). Multifocal disease was associated with shorter PFS and OS durations (p-value = 0.0011, 0.0015, respectively) among all patients. Conclusions In glioblastoma, PIK3CA, RB1, TERT promoter mutations, steroid use prior to start of CPI, and multifocal disease may be associated with a poor response to CPI while increased length of CPI may be associated with improved response. Our results may provide the rationale for clinical trials combining PI3K inhibitors with CPI in glioblastoma. The small sample size and retrospective nature of the study carries selection bias and/or confounding effects and larger studies need to be done to validate these results.Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironmentsNature Communications, 2023
- Management of brain metastases according to molecular subtypesNature Reviews Neurology, 2020
- A decade of immune-checkpoint inhibitors in cancer therapyNature Communications, 2020
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent GlioblastomaJAMA Oncology, 2020
- Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastomaNature Medicine, 2019
- Cancer-Associated PIK3CA Mutations in Overgrowth DisordersTrends in Molecular Medicine, 2018
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitorsInternational Immunopharmacology, 2018
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel ImmunotherapySeminars in Oncology, 2010
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Statistical Methods for the Analysis of Biomedical Data2002